**Supplementary material**

**Supplementary table 1.** Quantification of project impact, including individual and aggregated cost estimates.

|  |  |
| --- | --- |
| **Impact measure in AD-RIDDLE** | **Value** |
| *Reduction of specialized costly testing in early AD diagnosis* | |
| Estimated number of people with AD (prodromal AD and dementia) seeking care / year in Europe | 4 000 000 (1, 2) |
| % Diagnosed in specialised care | 83% (3) |
| % increase in toolbox platform use over 10 years\* | 10% |
| Number of patients impacted\*\* | 3 320 000 |
| % decrease in lumbar punctures\* | 2% |
| Avoided CSF tests\*\* | 66 400 |
| CSF-related cost per sample | 750 EUR (4) |
| Avoided CSF costs\*\* | 49 800 000 EUR |
| % decrease in amyloid-PET scans\* | 0.5% |
| Avoided PET costs\*\* | 16 600 |
| PET-related cost per scan | 1350 EUR (4) |
| Avoided PET costs\*\* | 22 410 000 EUR |
| % decrease in neuropsychological testing time\* | 10% |
| Number of patients needing specialized testing (prodromal AD) | 1 660 000 (1, 2) |
| Neuropsychological testing related cost per assessment | 500 EUR (4) |
| Reduction in testing cost\*\* | 83 000 000 EUR |
| Total costs avoided\*\* | 155 210 000 EUR |
| *Impact of improved early AD diagnosis on appropriate use of DMTs* | |
| Number of people with AD (prodromal AD and dementia) seeking care / year in Europe | 4 000 000 (1, 2) |
| % AD misdiagnosed in specialized care | 30% (5) |
| % patients eligible for DMTs | 10% |
| Number of DMT-eligible patients impacted\*\* | 120 000 |
| Improved early AD diagnosis leading to appropriate DMT use\* | 10% (6) |
| Number of DMT-eligible patients impacted\*\* | 12 000 |
| Value of appropriate use | 5 700 EUR (7) |
| Value of improved use\*\* | 68 400 000 EUR |
| *Impact of improved dementia risk detection and prevention in primary care (based on the FINGER model)* | |
| Number of patients with high risk of dementia identified | 22.56 million (1, 8) |
| Share participating in FINGER intervention program\* | 5% |
| Net monetary benefit per patient of participating in FINGER program | 3745 EUR (9) |
| Value of dementia risk detection and prevention\*\* | 4.2 billion EUR |

In green cells are listed areas of impact, while in blue cells are listed estimated AD-RIDDLE project impact.

Abbreviations: AD, Alzheimer's disease; CSF: cerebrospinal fluid; DMT, disease-modifying therapies; FINGER, Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability; PET, Positron Emission Tomography.

\* Estimation-based value for impact in the AD-RIDDLE project. \*\* Calculated value.

**References**

1. World Health Organization. Global status report on the public health response to dementia. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO. 2021. https://www.who.int/publications/i/item/9789240033245 Accessed 14 January 2024
2. Wolters FJ, Chibnik LB, Waziry R, Anderson R, Berr C, Beiser A, et al. Twenty-seven-year time trends in dementia incidence in Europe and the United States: The Alzheimer Cohorts Consortium. Neurology. 2020;95(5):e519-e31. doi:10.1212/WNL.0000000000010022
3. AE. Alzheimer Europe. European Carers’ Report 2018: Carers’ experiences of diagnosis in five European countries. 2018 https://www.alzheimer-europe.org/resources/publications/2018-european-carers-report-carers-experiences-diagnosis-five-european Accessed 14 January 2024.
4. Gauthier S, Rosa-Neto P, Morais JA, Webster C. World Alzheimer Report 2021: Journey through the diagnosis of dementia. London, England: Alzheimer’s Disease International. https://www.alzint.org/u/World-Alzheimer-Report-2021.pdf Accessed 14 January 2024.
5. Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954-63. doi:10.1038/s41591-021-01382-x
6. Anderson TS, Ayanian JZ, Souza J, Landon BE. Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment. JAMA. 2021;326(16):1627-9. doi:10.1001/jama.2021.15286
7. ICER. Institute for Clinical and Economic Review. https://icer.org/ Accessed 14 January 2024
8. Ngandu T, Lehtisalo J, Levalahti E, Laatikainen T, Lindstrom J, Peltonen M, et al. Recruitment and baseline characteristics of participants in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER)-a randomized controlled lifestyle trial. Int J Environ Res Public Health. 2014;11(9):9345-60. doi:https://doi.org/10.3390/ijerph110909345
9. Wimo A, Handels R, Antikainen R, Eriksdotter M, Jonsson L, Knapp M, et al. Dementia prevention: The potential long-term cost-effectiveness of the FINGER prevention program. Alzheimers Dement. 2022. doi:10.1002/alz.12698